GSK meningococcal ABCWY vaccine candidate accepted for FDA review

GSK plc announced that the U.S. Food and Drug Administration has accepted for review a Biologics License Application, or BLA, for its 5-in-1 meningococcal ABCWY vaccine candidate. The Prescription Drug User Fee Act, or PDUFA, goal date for a decision by the US FDA on this application is February 14, 2025.